0001415889-24-011705.txt : 20240429 0001415889-24-011705.hdr.sgml : 20240429 20240429181103 ACCESSION NUMBER: 0001415889-24-011705 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240425 FILED AS OF DATE: 20240429 DATE AS OF CHANGE: 20240429 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Posard Matthew L. CENTRAL INDEX KEY: 0001543792 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-32335 FILM NUMBER: 24893260 MAIL ADDRESS: STREET 1: 11099 N. TORREY PINES ROAD STREET 2: SUITE 100 CITY: LA JOLLA STATE: CA ZIP: 92037 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: HALOZYME THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001159036 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 880488686 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 12390 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 794-8889 MAIL ADDRESS: STREET 1: 12390 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 FORMER COMPANY: FORMER CONFORMED NAME: HALOZYME THERAPEUTICS INC DATE OF NAME CHANGE: 20040312 FORMER COMPANY: FORMER CONFORMED NAME: GLOBAL YACHT SERVICES INC DATE OF NAME CHANGE: 20010912 4 1 form4-04292024_100445.xml X0508 4 2024-04-25 0001159036 HALOZYME THERAPEUTICS, INC. HALO 0001543792 Posard Matthew L. C/O HALOZYME THERAPEUTICS, INC. 12390 EL CAMINO REAL SAN DIEGO CA 92130 true false false false 0 Common Stock 2024-04-25 4 A 0 6501 0 A 119755 D Option to Purchase Common Stock 38.46 2024-04-25 4 A 0 8804 0 A 2034-04-25 Common Stock 8804 8804 D Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) April 25, 2025 and (ii) the date of the Issuer's next annual meeting of stockholders. These stock units are subject to a written deferral election under the Issuer's Directors Deferred Equity Compensation Plan pursuant to which shares of common stock are released to the reporting person upon completion of service as a director. Represents annual stock option grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) April 25, 2025 and (ii) the date of the Issuer's next annual meeting of stockholders. /s/ James Oehler, Attorney-in-Fact 2024-04-29